PMID- 33989086
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20220423
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 24
IP  - 1
DP  - 2021 Jan-Dec
TI  - Economic evaluation of home medication review by community pharmacists (HMR-CP) 
      for patients with type 2 diabetes mellitus (T2DM).
PG  - 730-740
LID - 10.1080/13696998.2021.1889573 [doi]
AB  - OBJECTIVE: Home medication review (HMR) programs could minimise patients' 
      health-related costs and burdens, thereby enhancing the quality of life and 
      well-being. The aim of this economic evaluation is to determine if home 
      medication review by community pharmacists (HMR-CP) for patients with type 2 
      diabetes mellitus (T2DM) is a cost-effective intervention from the Malaysian 
      healthcare provider perspective. METHODS: The economic evaluation was conducted 
      alongside the randomised controlled trial (RCT) to estimate the intermediate 
      cost-effectiveness of HMR-CP for patients with T2DM. A Markov model was then 
      constructed to project the lifetime cost-effectiveness data beyond the RCT. The 
      primary outcomes for the economic evaluation were HbA(1c) and quality-adjusted 
      life-years (QALYs). RESULTS: The intervention and health services costs 
      throughout the 6-month HMR-CP trial were RM121.45 (USD28.64) [95%CI: RM115.89 to 
      127.08 (USD27.33-29.97)] per participant. At a 6-month follow-up, a significant 
      reduction in HbA(1c) of 0.902% (95% CI: 0.388% to 1.412%) was noted in the HMR-CP 
      group compared to the control group. The ICER of HMR-CP intervention versus 
      standard care was RM178.82 (USD 42.17) [95%CI: RM86.77-364.03 (USD20.46-85.86)] 
      per reduction of HbA(1c). HMR-CP intervention [RM12,764.82 (USD3010.57)] was 
      associated with an incremental cost of RM83.34 (USD19.66) over control group 
      [RM12,682.95 (USD2,991.26)] with an additional of 0.07 QALY gained. The ICER 
      associated with HMR-CP intervention was RM1,190.57 (USD280.79) per QALY gained, 
      which was below the ICER threshold in Malaysia, indicating that HMR-CP was a 
      cost-effective option. CONCLUSION: HMR-CP was a cost-effective intervention that 
      had significantly reduced the HbA(1c) among the T2DM patients, although 
      associated with higher mean total costs per participant.
FAU - Rosli, Mohd Rozaini
AU  - Rosli MR
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, Universiti Teknologi MARA, 
      Cawangan Selangor, Kampus Puncak Alam, Selangor, Malaysia.
FAU - Wu, David Bin-Chia
AU  - Wu DB
AD  - School of Pharmacy, Monash University Malaysia, Selangor, Malaysia.
AD  - Asian Centre for Evidence Synthesis in Population, Implementation and Clinical 
      Outcomes (PICO), Health and Well-being Cluster, Global Asia in the 21st Century 
      (GA21) Platform, Monash University Malaysia, Selangor, Malaysia.
AD  - Saw Swee Hock School of Public Health, National University of Singapore, 
      Singapore.
FAU - Neoh, Chin Fen
AU  - Neoh CF
AUID- ORCID: 0000-0003-2462-2958
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, Universiti Teknologi MARA, 
      Cawangan Selangor, Kampus Puncak Alam, Selangor, Malaysia.
AD  - Collaborative Drug Discovery Research (CDDR) Group, Pharmaceutical and Life 
      Sciences Community of Research, Universiti Teknologi MARA, Selangor, Malaysia.
FAU - Karuppannan, Mahmathi
AU  - Karuppannan M
AUID- ORCID: 0000-0002-6503-3191
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, Universiti Teknologi MARA, 
      Cawangan Selangor, Kampus Puncak Alam, Selangor, Malaysia.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
SB  - IM
MH  - Cost-Benefit Analysis
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Humans
MH  - *Pharmacists
MH  - Quality of Life
MH  - Quality-Adjusted Life Years
OTO - NOTNLM
OT  - C51 - Model Construction and Estimation
OT  - Cost-utility
OT  - Z19 - Other
OT  - diabetes
OT  - home medication review
OT  - pharmacy
EDAT- 2021/05/15 06:00
MHDA- 2021/09/30 06:00
CRDT- 2021/05/14 17:14
PHST- 2021/05/15 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2021/05/14 17:14 [entrez]
AID - 10.1080/13696998.2021.1889573 [doi]
PST - ppublish
SO  - J Med Econ. 2021 Jan-Dec;24(1):730-740. doi: 10.1080/13696998.2021.1889573.